Leo Pharma

LEO Pharma Inc. Announces U.S. FDA approval of Adbry® (tralokinumab-ldrm) for the Treatment of Moderate-to-severe Atopic Dermatitis in Pediatric Patients Aged 12-17 Years

Retrieved on: 
Friday, December 15, 2023

This critical patient group now has access to a much-needed additional treatment option to manage their atopic dermatitis," said Brian Hilberdink, EVP and President, Region North America, LEO Pharma, “We are delighted to be able to offer Adbry, a highly targeted treatment, to both adult and pediatric patients in the U.S.

Key Points: 
  • This critical patient group now has access to a much-needed additional treatment option to manage their atopic dermatitis," said Brian Hilberdink, EVP and President, Region North America, LEO Pharma, “We are delighted to be able to offer Adbry, a highly targeted treatment, to both adult and pediatric patients in the U.S.
  • *1
    The approval is based on data from the Phase 3 ECZTRA 6 trial, which evaluated the efficacy and safety of Adbry in 289 pediatric patients aged 12-17 years with moderate-to-severe AD who were candidates for systemic therapy.
  • A total of 98 patients received an initial dose of Adbry 300 mg followed by 150 mg every other week up to Week 16.
  • “Such advances in the atopic dermatitis treatment landscape provide much-needed hope for pediatric patients seeking a long-term treatment option that could work for them.”
    Dr. Paller is an ECZTRA 6 clinical trial investigator and a paid consultant of LEO Pharma Inc.

Secura Bio Announces the Addition of Two New Board of Directors Members

Retrieved on: 
Thursday, December 7, 2023

SUMMERLIN, Nev., Dec. 7, 2023 /PRNewswire/ -- Secura Bio, Inc. (Secura Bio) - ( www.securabio.com ), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, today announces that it has added two members to the board of directors of Secura Bio Holdings, Inc.

Key Points: 
  • SUMMERLIN, Nev., Dec. 7, 2023 /PRNewswire/ -- Secura Bio, Inc. (Secura Bio) - ( www.securabio.com ), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, today announces that it has added two members to the board of directors of Secura Bio Holdings, Inc.
  • The new members are Joerg Moeller, MD and Charles (Chip) R. Romp.
  • He was the former Head of Global Research and Development at Bayer Pharmaceuticals and a member of Bayer Pharma´s Executive Committee.
  • With his addition to the board, Chip Romp stated, "I am thrilled to join the board of directors and look forward to working with the company's leadership to improve the lives of patients".

Cerba HealthCare Changes Its Governance and Appoints Emmanuel Ligner Group Chief Executive Officer

Retrieved on: 
Thursday, November 9, 2023

Cerba HealthCare, a leading player in medical diagnostics, announces the appointment of Emmanuel Ligner as Chief Executive Officer of the Group.

Key Points: 
  • Cerba HealthCare, a leading player in medical diagnostics, announces the appointment of Emmanuel Ligner as Chief Executive Officer of the Group.
  • Cerba HealthCare aims to remain at the forefront of medical innovation to help develop new treatments and improve patient health.
  • Emmanuel Ligner, Group Chief Executive Officer, said: « Cerba HealthCare is a leading company in the field of medical diagnostics as evidenced by the Group’s growth and the importance it has placed on innovation since its very inception.
  • »
    Jérôme Thill, Senior Advisor and former Chief Executive Officer of the Group, adds: « As I step down as Chief Executive Officer, I would like to thank all of Cerba HealthCare’s teams and partners.

Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors

Retrieved on: 
Wednesday, November 1, 2023

Bill Lis is stepping down as Chairperson and will retire from the Board in December of this year.

Key Points: 
  • Bill Lis is stepping down as Chairperson and will retire from the Board in December of this year.
  • “We are pleased to welcome Tom to our Board as Chairperson.
  • “I will be supporting Tom, Ron, and the rest of Jasper as I transition off the Jasper Board to new company ventures.”
    Mr. Wiggans most recently served as Chairman and CEO of Pardes Biosciences.
  • He began his career with Eli Lilly & Co. Mr. Wiggans is currently on the Board of Directors of Annexon, Inc., and Cymabay Therapeutics Inc.

LEO Pharma Announces Positive Outcome of DELTA 3 Open-Label Extension Trial of Delgocitinib Cream in the Treatment of Adults With Moderate to Severe Chronic Hand Eczema (CHE)

Retrieved on: 
Monday, October 30, 2023

LEO Pharma A/S, a global leader in medical dermatology, today announced the positive outcome of the DELTA 3 trial.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today announced the positive outcome of the DELTA 3 trial.
  • DELTA 3 is a phase 3, single-arm, open-label extension trial of delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
  • All DELTA 3 trial subjects had completed the DELTA 1 or DELTA 2 trials and were offered to immediately enroll into this extension trial.
  • Furthermore, patients who entered the DELTA 3 trial after receiving cream vehicle in the DELTA 1 and DELTA 2 trials reached similar levels of treatment success as the patients previously treated with delgocitinib cream.

Montai Health Appoints Christian Antoni, M.D., Ph.D., as Company’s First Chief Medical Officer

Retrieved on: 
Tuesday, October 24, 2023

CAMBRIDGE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Montai Health, a company solving the chronic disease challenge by connecting complex biology to untapped human chemistry with AI to improve patients’ lives, today announced the appointment of Christian Antoni, M.D., Ph.D., as Chief Medical Officer. Dr. Antoni will lead the company’s development of scalable and efficient clinical operating capabilities to translate into the clinic a rapidly expanding pipeline of potential first-in-class oral therapies with an initial focus on chronic inflammatory and autoimmune diseases.

Key Points: 
  • Montai Health Appoints Christian Antoni, M.D., Ph.D., as Chief Medical Officer
    A rheumatologist by training, Dr. Antoni most recently was the Chief Development Officer at EQRx.
  • Montai’s CONECTA™ Platform is enabling breakthroughs in predictably developing first-in-class small-molecule medicines with potential for long-term safety and earlier intervention.
  • Changing this model has the potential to transform patient outcomes at scale.”
    Dr. Antoni completed his medical training and residency in internal medicine and rheumatology at Friedrich-Alexander University, Germany.
  • Dr. Antoni joins an industry-leading scientific and drug development team with decades of collective experience bringing novel, impactful medicines to the clinic across multiple therapeutic areas, including:

LEO Pharma Presents Adbry® (tralokinumab-ldrm) Data at 2023 Fall Clinical Dermatology Conference

Retrieved on: 
Friday, October 20, 2023

LEO Pharma A/S, a global leader in medical dermatology, will present a catalog of new clinical and real-world data around tralokinumab-ldrm in the treatment of moderate-to-severe atopic dermatitis (AD).

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, will present a catalog of new clinical and real-world data around tralokinumab-ldrm in the treatment of moderate-to-severe atopic dermatitis (AD).
  • The drug is marketed in the U.S. as Adbry® for adult patients (aged 18+ years) with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
  • The findings are being presented across 12 posters at the 2023 Fall Clinical Dermatology Conference taking place in Las Vegas, Nevada, from October 19-22, 2023.1-12
    “We are thrilled to present such a wealth of tralokinumab-ldrm data, which will further develop our understanding of how to meet the needs of patients living with atopic dermatitis,” says Kreesten Meldgaard Madsen, Chief Development Officer, LEO Pharma.
  • “The breadth and depth of LEO Pharma data being presented at the Fall Clinical Dermatology Conference this year will showcase our leadership in the medical dermatology space and our continued commitment to the whole patient community.

LEO Pharma Presents New Long-Term Data on Use of Adtralza® (tralokinumab) to Treat Moderate-to-Severe Atopic Dermatitis (AD)

Retrieved on: 
Friday, October 13, 2023

LEO Pharma A/S, a global leader in medical dermatology, today presented new data assessing the long-term safety and efficacy data of continuous treatment with Adtralza® (tralokinumab) over four years for moderate-to-severe atopic dermatitis (AD) in adults.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today presented new data assessing the long-term safety and efficacy data of continuous treatment with Adtralza® (tralokinumab) over four years for moderate-to-severe atopic dermatitis (AD) in adults.
  • The analysis was of participants from ECZTEND who had previously enrolled in the ECZTRA 1 and 2 phase 3 trials.
  • Again, the pattern of adverse events (AEs) was consistent with the initial placebo-controlled treatment period and with no new safety signals identified.
  • “We aim to use this long-term and real-world evidence to build upon Adtralza’s existing foundation of research.”

Temtokibart achieves First Subject First Treatment (FSFT) milestone in Phase 2b trial

Retrieved on: 
Wednesday, October 11, 2023

LEO Pharma A/S, a global leader in medical dermatology, has today announced the First Subject First Treatment (FSFT) milestone for the Phase 2b clinical trial for temtokibart, LEO Pharma's IL-22RA1 antibody.2 The first patient dose was successfully administered on the 4th of October at the DermEdge Research Center in Ontario, Canada.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, has today announced the First Subject First Treatment (FSFT) milestone for the Phase 2b clinical trial for temtokibart, LEO Pharma's IL-22RA1 antibody.2 The first patient dose was successfully administered on the 4th of October at the DermEdge Research Center in Ontario, Canada.
  • Temtokibart is an investigational monoclonal antibody currently in Phase 2 development for the treatment of moderate-to-severe atopic dermatitis (AD).
  • “By targeting the IL-22 pathway, this trial could provide additional insights into the pathophysiology of atopic dermatitis.”
    The Phase 2b trial will be overseen by a specialist steering committee, the purpose of which is to provide critical scientific guidance, oversee trial conduct and drive trial results, analysis and scientific communications.
  • LEO Pharma obtained the license to temtokibart in 2022 and now assumes the responsibility to develop and commercialize the drug for inflammatory skin disorders, such as AD.

Globally Known Professor and Dermatologist Joins LEO Pharma

Retrieved on: 
Monday, October 9, 2023

LEO Pharma A/S, a global leader in medical dermatology, is today announcing the appointment of Professor Alexander Egeberg, a globally recognized dermatologist and top key opinion leader as the company’s new Vice President, Head of Global Medical Affairs.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, is today announcing the appointment of Professor Alexander Egeberg, a globally recognized dermatologist and top key opinion leader as the company’s new Vice President, Head of Global Medical Affairs.
  • Alexander Egeberg joins LEO Pharma from a role as Professor of Dermatology at the University of Copenhagen and head of one of the largest clinics in Northern Europe for biologic therapy at Bispebjerg Hospital's Department of Dermatology.
  • He is a globally known professor and a board-certified dermatologist with an extensive research and clinical background.
  • “I am genuinely excited to join LEO Pharma as Vice President, Head of Global Medical Affairs.